Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Shigeya Uejima"'
Autor:
Naoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, Yutaka Yamamoto, Ken Kuwahara, Yasuharu Nagai, Takafumi Minami, Yuji Hatanaka, Masahiro Nozawa, Yasuhiro Morimoto, Hideo Tahara, Shigeya Uejima, Atsunobu Esa, Akihide Hirayama, Kazuhiro Yoshimura, Hirotsugu Uemura
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cance
Externí odkaz:
https://doaj.org/article/f92ba2e2dfeb49a58807315bbf859ffa
Autor:
Kazuhiro Nagao, Hideyasu Matsuyama, Masahiro Nozawa, Isao Hara, Tsukasa Nishioka, Takahiro Komura, Atsunobu Esa, Shigeya Uejima, Masaaki Imanishi, Yasunari Uekado, Takatoshi Ogawa, Hiroshi Kajikawa, Hirotsugu Uemura
Publikováno v:
Asian Journal of Urology, Vol 3, Iss 1, Pp 33-38 (2016)
Objective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared.
Externí odkaz:
https://doaj.org/article/ca62a73c993f4192813c7f49c66fa070
Autor:
Shiro Ohshima, Fumihiko Nakanishi, Mami Yamaguchi, Mai Kakiuchi, Takuhide Utunomiya, Saki Nakajima, Keita Kudo, Shigeya Uejima, Tetsuya Horiuchi
Publikováno v:
Annals of Oncology. 32:S301
Publikováno v:
Hinyokika kiyo. Acta urologica Japonica. 64(11)
A 75-year-old man with a history of early gastric cancer, phimosis and bronchial asthma experienced pain and palpated a mass in the penis in March 2015. After 2 months, he noticed bleeding from the tumor and visited our hospital. Pelvic computed tomo
Autor:
Takahiro Akiyama, Takafumi Minami, Koichi Sugimoto, Naoki Matsumura, Shigeya Uejima, Hirotsugu Uemura
Publikováno v:
International Journal of Urology. 26:848-849
Autor:
Hirotsugu Uemura, Kyogo Itoh, Motoyoshi Tanaka, Shigeya Uejima, Kazuhiro Yoshikawa, Kiyohide Fujimoto, Yoshihiko Hirao, M Yoshikawa
Publikováno v:
Clinical Cancer Research. 12:1768-1775
Purpose: A phase I peptide vaccination trial was done in patients with progressive cytokine-refractory metastatic renal cell carcinoma (RCC) to assess both the toxicity and capability to induce immune responses of three peptides (CA9p219-227, p288-29
Autor:
Masayuki Iki, Masahiro Nozawa, Hirotsugu Uemura, Hideyasu Matsuyama, Takatoshi Ogawa, Shigeya Uejima, Yasunari Uekado, Tsukasa Nishioka, Atsunobu Esa, Hiroshi Kajikawa, Isao Hara, Masaaki Imanishi, Kazuhiro Nagao, Takahiro Komura
Publikováno v:
World journal of urology. 33(9)
This study evaluated the baseline patient characteristics associated with the time to biochemical progression and overall survival in patients who participated in a phase II trial on zoledronic acid combined with the initial androgen-deprivation ther
Autor:
Atsunobu Esa, Tsukasa Nishioka, Takeshi Inagaki, Hirotsugu Uemura, Shigeya Uejima, Hiroshi Kajikawa, Masaaki Imanishi, Takahiro Komura, Masahiro Nozawa, Kazuhiro Nagao, Isao Hara, Michio Kitagawa, Hideyasu Matsuyama, Yasunari Uekado, Takatoshi Ogawa
Publikováno v:
International journal of clinical oncology. 19(4)
The efficacy of zoledronic acid in patients with treatment-naïve prostate cancer is unclear. We conducted a phase II study to investigate the benefits of combined zoledronic acid and androgen deprivation therapy in treatment-naïve prostate cancer w
Autor:
Kyogo Itoh, Hirotsugu Uemura, Akira Yamada, Shigeya Uejima, Nobukazu Komatsu, Yoshihiko Hirao, Marco A. De Velasco, Takashi Mine, Kiyohide Fujimoto
Publikováno v:
Cancer science. 101(3)
We previously reported that personalized peptide vaccine (PPV) therapy in combination with leutenizing hormone-releasing hormone (LH-RH) analog and estramustine phosphate in certain cases is safe and capable of inducing both immune responses and clin
Publikováno v:
Urological Research. 19:215-218
The growth fraction of bladder tumors was immunohistochemically assessed in situ using anti-DNA polymerase (Pol alpha) monoclonal antibody. This enzyme is known to be present in the nucleus of the cells in G1, S, and G2 phases. The percentage of labe